Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Cabotegravir Phase III Formulations
NCT02345707Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time zero to infinity, Area under the concentration-time curve from time zero to the last quantifiable concentration and 2 more. Started Mar 2015; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02345707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345707.